Reprint

Molecular Features Distinguishing Gastric Cancer Subtypes

Edited by
November 2018
326 pages
  • ISBN978-3-03897-404-8 (Paperback)
  • ISBN978-3-03897-405-5 (PDF)

This is a Reprint of the Special Issue Molecular Features Distinguishing Gastric Cancer Subtypes that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Gastric cancer is a leading cause of cancer deaths, but analysis of its molecular and clinical characteristics has been complicated by histological and aetiological heterogeneity. Stomach cancers are 90% adenocarcinoma; lymphoma, carcinoid, and stromal tumours may occur.  Adenocarcinoma can be subdivided into histological Lauren and the World Health Organization (WHO) classifications, but this information has not led to the development of histologic subtype-specific treatment options. One way to potentially improve treatment for gastric cancers is to better understand the pathogenesis of this disease, the contribution of Helicobacter pylori infection, and host immune response to lead to the development of integrated histological and molecular classification schemes for gastric cancer. The hope is that these studies may facilitate the development of clinical trials to explore therapies in defined sets of patients, ultimately improving survival from this deadly disease.

Format
  • Paperback
License and Copyright
© 2019 by the authors; CC BY license
Keywords
gastric cancer; MALDI imaging; proteomics; metabolomics; lipidomics; Hereditary Diffuse Gastric Cancer; E-cadherin; CDH1 missense variants; functional characterization; diagnostic tools; E-cadherin; CDH1; HER2; metastatic gastric cancer; rs16260; rs1801552; autoimmune diseases; autoimmune gastritis; gastric cancer; Helicobacter pylori infection; intrinsic factor antibodies; parietal cell antibodies; common variable immunodeficiency; gastric cancer; human immunoglobulins; lymphoproliferative disorders; gastric cancer; metabolomics; first degree relatives; biomarkers; early diagnosis; pepsinogen; DIGE; comparative proteomics; gastric cancer; fibrinogen β chain; FGB; coagulation; platelets; biomarker; flow cytometry; gastric epithelium; autoimmune gastritis; atrophic gastritis; H. pylori; gastric microbiota; gastric cancer; pro-inflammation; CCL5; CCR5; gastric cancer; tumor microenvironment; invasion; CCR5 antagonists; gastric cancer; immunotherapy; immune checkpoint; chimeric antigen receptor; cancer vaccine; adoptive immunotherapy; Epstein–Barr virus; microsatellite instability; tumor microenvironment; gastric cancer; HER2; cell cycle regulators; microsatellite instability; apoptosis; mucins; multidrug resistance proteins; invasiveness; peritoneal spreading; neovascularization; gastric cancer; lynch syndrome; familial adenomatous polyposis (FAP), helicobacter pylori infection; autoimmune gastritis; fundic gland polyps (FGPs); gastric cancer; gene expression profile; gene mutation; molecular gastric cancer subtype; EBV infection; microsatellite; preclinical models; miRNA; gastric cancer; reprimo; tumor suppressive gene properties; development; evolution; biomarker; gastric cancer; transcriptomic profiling; Epstein-Barr Virus; EBV; microsatellite instability; MSI; gastric cancer; diffuse gastric cancer; hereditary diffuse gastric cancer; contributing factors; gastric cancer; molecular classifications; targeted therapy; immunotherapy; H. pylori; RONS; BER; DSBs; NF-κB; NER; n/a

Related Books